About Us

---

 Dynamix Biotechnology Inc. - DBI is a rapidly emerging biotech company  dedicated  to  the  commercialization  of  a  treatment  for  Sarcoidosis.   

 Currently focusing efforts on DB-602, an injectable peptide that in extensive studies conducted has shown a greater efficacy than current FDA approved treatments. 

 Technology developed by Dr Andrew Schally, a Noble Prize winning Endooncologist and Dr Mehdi MirSaeidi who is the Chief of Pulmonology division at the University of Florida (UF)